The company also expects to commence dosing patients with mild to moderate Alzheimer’s disease in a Phase 2a clinical trial in the next several weeks.
“This study has provided us with valuable information about the safety and tolerability of MEM 1003 in Alzheimer’s patients, which has been integral to the design of the Phase 2a clinical trial,” said Dr David Lowe, chief scientific officer of Memory Pharmaceuticals. “We are now moving forward into the Phase 2a clinical trial with a solid understanding of the safety and pharmacokinetic parameters for this drug candidate.”
The Phase 2a proof of concept study for MEM 1003 will evaluate the safety and efficacy of MEM 1003 in patients with mild to moderate Alzheimer’s disease.
The safety and tolerability study consisted of two segments, a double-blind dose escalation phase and a double-blind treatment phase. In the first segment of the study MEM 1003 or placebo was administered to 49 patients two times on one day. Patients in this segment of the study were treated at escalating doses of MEM 1003 that reached 120 milligrams per dose. In the double-blind treatment segment, 32 patients received 120 mg of MEM 1003 or placebo twice daily for a period of ten days.